The Experts below are selected from a list of 223941 Experts worldwide ranked by ideXlab platform
K.h. Liew - One of the best experts on this subject based on the ideXlab platform.
-
Radiation myelopathy following transplantation and radiotherapy for non–Hodgkin’s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
-
radiation myelopathy following transplantation and radiotherapy for non hodgkin s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
Michael W.t Chao - One of the best experts on this subject based on the ideXlab platform.
-
Radiation myelopathy following transplantation and radiotherapy for non–Hodgkin’s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
-
radiation myelopathy following transplantation and radiotherapy for non hodgkin s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
Andrew Wirth - One of the best experts on this subject based on the ideXlab platform.
-
Radiation myelopathy following transplantation and radiotherapy for non–Hodgkin’s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
-
radiation myelopathy following transplantation and radiotherapy for non hodgkin s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
Gail Ryan - One of the best experts on this subject based on the ideXlab platform.
-
Radiation myelopathy following transplantation and radiotherapy for non–Hodgkin’s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
-
radiation myelopathy following transplantation and radiotherapy for non hodgkin s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
Michael Macmanus - One of the best experts on this subject based on the ideXlab platform.
-
Radiation myelopathy following transplantation and radiotherapy for non–Hodgkin’s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
-
radiation myelopathy following transplantation and radiotherapy for non hodgkin s lymphoma
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Michael W.t Chao, Michael Macmanus, Andrew Wirth, Gail Ryan, K.h. LiewAbstract:Abstract Background: Combined modality therapy with chemotherapy and radiotherapy has become increasingly popular in the management of solid malignancies. However, unexpected toxicities may arise from their Interactions. Methods and Materials: We report the case of a young woman with a large mediastinal non–Hodgkin’s lymphoma who underwent high-dose chemotherapy with autologous bone marrow transplantation and involved field radiotherapy, and who developed radiation myelopathy after a latent period of only 3 months. The spinal cord dose did not exceed 40.3 Gy in 22 fractions over 4.5 weeks, which is well within accepted tolerance limits. She had no other identifiable risk factors for radiation myelopathy, suggesting an adverse drug–radiation Interaction as the most likely cause of her injury. Results and Conclusions: This represents the first report of radiation myelopathy at accepted safe radiation doses following high-dose chemotherapy with autologous bone marrow transplantation, and we recommend caution in the choice of radiotherapeutic dose in this setting.
